

Cutaneous adverse reactions in B-RAF positive metastatic melanoma treatment with B-RAF/MEK inhibitors and immune checkpoint inhibitors: a single-institutional case-series

DOI: [10.1186/s40425-018-0475-y](https://doi.org/10.1186/s40425-018-0475-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A patent review of RAF kinase inhibitors (2010–2018). Expert Opinion on Therapeutic Patents, 2019, 29, 675-688.	5.0	13
3	Atypical features of cutaneous adverse drug reactions during therapy for hairy cell leukemia. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3203-3206.e1.	3.8	4
4	Systematic review of BRAF/MEK inhibitors–induced Severe Cutaneous Adverse Reactions (SCARs). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 607-614.	2.4	26
5	Posterior Reversible Encephalopathy Syndrome (PRES) and Drug-Induced Hypersensitivity Syndrome (DIHS) following Immunotherapy and BRAF/MEK Inhibition with Continued Response in Metastatic Melanoma. Case Reports in Oncological Medicine, 2021, 2021, 1-5.	0.3	4
6	Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in Oncology, 2021, 11, 672172.	2.8	2
7	Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy. JAAD Case Reports, 2021, 13, 147-151.	0.8	4
8	Maculopapular erythema caused by previously used chemotherapy drugs after nivolumab treatment for malignant mesothelioma. Journal of Cutaneous Immunology and Allergy, 2021, 4, 178-180.	0.3	0
9	Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review. Supportive Care in Cancer, 2022, 30, 2839-2851.	2.2	1
10	Dress syndrome secondary to different combinations of targeted therapy (iBRAF + iMEK). European Journal of Dermatology, 2020, 30, 303-304.	0.6	2
11	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	1.6	580
12	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC Cancer, 2021, 21, 1187.	2.6	6
13	Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma. Acta Dermato-Venereologica, 2022, , .	1.3	1
14	Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies: A multicenter retrospective study. Journal of the American Academy of Dermatology, 2023, 88, 474-476.	1.2	0
15	Cutaneous Reactions to Oncologic Immunotherapy. Updates in Clinical Dermatology, 2022, , 317-330.	0.1	0
16	Etanercept leads to a rapid recovery of a Dabrafenib–Trametinib–associated toxic epidermal necrolysis–like severe skin reaction. Skin Health and Disease, 0, , .	1.5	0
17	Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone. Open Life Sciences, 2023, 18, .	1.4	0
18	Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies. Cancers, 2023, 15, 3126.	3.7	1